Gunnar Gislason

As the dust continues to settle on the Vioxx issue, there is naturally a desire to look further at potential cardiovascular risks associated with COX-2 inhibitors and, indeed, other non-steroidal anti-inflammatories. Gunnar Gislason from Bispebjerg University Hospital has …